IQVIA shares fell approximately 8.5 to 9 percent following the company's fourth-quarter 2025 earnings announcement on February 5. While the company beat Wall Street expectations with quarterly earnings of $3.42 per share versus an estimated $3.40 per share, and exceeded revenue forecasts, the stock decline was driven by weak full-year 2026 profit guidance. The company forecast annual profit below Wall Street expectations, citing higher interest expenses as a primary headwind. For 2026, IQVIA provided revenue guidance between $17.15 billion and $17.35 billion and adjusted EBITDA guidance of $3.975 billion to $4.025 billion. Despite strong fourth-quarter results reflecting improving demand from pharmaceutical clients, the below-consensus profit outlook for the full year prompted the market reaction.
Read full analysisIQVIA shares fell approximately 8.5 to 9 percent following the company's fourth-quarter 2025 earnings announcement on February 5. While the company beat Wall Street expectations with quarterly earnings of $3.42 per share versus an estimated $3.40 per share, and exceeded revenue forecasts, the stock decline was driven by weak full-year 2026 profit guidance. The company forecast annual profit below Wall Street expectations, citing higher interest expenses as a primary headwind. For 2026, IQVIA provided revenue guidance between $17.15 billion and $17.35 billion and adjusted EBITDA guidance of $3.975 billion to $4.025 billion. Despite strong fourth-quarter results reflecting improving demand from pharmaceutical clients, the below-consensus profit outlook for the full year prompted the market reaction.
IQVIA Holdings Inc. (IQV) is a publicly traded company in the Healthcare sector.